Intraperitoneal vascular endothelial growth factor burden in peritoneal surface malignancies treated with curative intent: The first step before intraperitoneal anti-vascular endothelial growth factor treatment?

Passot, Guillaume; Bakrin, Naoual; Garnier, L.; Roux, Adeline; Vaudoyer, D.; Wallet, Frédéric; Gilly, François Noël; Gléhen, Olivier; Cotte, Eddy

doi:10.1016/j.ejca.2013.11.005

Cited by 11 publications

(9 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The authors demonstrated a significant increase of the intraperitoneal levels of VEGF immediately after debulking surgery, followed by a consistent decrease in the next hours. Moreover, the authors demonstrated that the initial intraperitoneal VEGF levels were significantly associated with the risk of postoperative complications and underlined the fact that preoperative administration of Bevacizumab might decrease these levels and therefore, improve the outcomes of these patients 23 .…”

Section: Breast Cancer Originmentioning

confidence: 99%

“…In order to determine the potential factors which might influence the evolution of peritoneal carcinomatosis patients after debulking surgery and HIPEC, Passot et al conducted a study in which they investigated the influence of intraperitoneal vascular endothelial growth factor (VEGF) burden 23 . The study included 97 patients with peritoneal carcinomatosis from various origins submitted to debulking surgery between February and October 2012, the most commonly reported origins being colorectal and ovarian -each in 15 cases, followed by pseudomyxoma peritonei and gastric origin; among cases with other origins, one patient was diagnosed with peritoneal metastases from breast cancer origin.…”

Section: Breast Cancer Originmentioning

confidence: 99%

See 1 more Smart Citation

Diagnostic and therapeutic strategies in peritoneal carcinomatosis from breast cancer – literature minireview

Bacalbaşa¹,

Bălescu²,

Suciu³

et al. 2018

Arch Balk Med Union

View full text Add to dashboard Cite

Stratégies diagnostiques et thérapeutiques dans la carcinose péritonéale du cancer du sein-courte revue de la littérature La carcinose péritonéale d'origine cancéreuse est une situation peu commune, qui se développe généralement tardivement au cours de l'évolution de la maladie. Le développement de telles lésions est généralement associé à une histologie agressive (tel qu'un carcinome lobulaire) et à un stade avancé du diagnostic et est généralement associé à un résultat médiocre. Le diagnostic positif de la carcinose péritonéale d'origine cancéreuse du sein ne peut être maintenu que si une biopsie des nodules tumoraux démontre l'origine mammaire des lésions. Afin d'améliorer l'issue de ces patients, une chirurgie cytoréductionnelle, seule ou en association avec une chimiothérapie hyperthermique intrapéritonéale, a été proposée. Cependant, d'autres études sont encore nécessaires pour inclure

show abstract

Section: Breast Cancer Originmentioning

confidence: 99%

Section: Breast Cancer Originmentioning

confidence: 99%

Diagnostic and therapeutic strategies in peritoneal carcinomatosis from breast cancer – literature minireview

Bacalbaşa¹,

Bălescu²,

Suciu³

et al. 2018

Arch Balk Med Union

View full text Add to dashboard Cite

show abstract

“…High VEGF levels have been found in malignant ascites, and the introduction of VEGF antisense oligonucleotides decreased VEGF levels and inhibited ascites formation. 13–16 Bevacizumab is a humanized anti-human VEGF-A monoclonal antibody that specifically binds to VEGF, and it has been approved by the Food and Drug Administration for the treatment of several types of cancers, including colorectal, non-small-cell lung, renal, and ovarian cancers. 17 Bevacizumab is intravenously injected using common doses of 5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks.…”

Section: Introductionmentioning

confidence: 99%

Phase I study of intraperitoneal bevacizumab for treating refractory malignant ascites

Kou

Gong

et al. 2021

J Int Med Res

View full text Add to dashboard Cite

Objective This prospective, dose-escalation phase I study evaluated the safety and efficacy of intraperitoneal bevacizumab in managing refractory malignant ascites and explored the recommended dose of bevacizumab for further study. Methods Patients with refractory malignant ascites were enrolled. Bevacizumab was intraperitoneal administered weekly at an initial dose of 2.5 mg/kg, with dose escalation to 5 and 7.5 mg/kg performed following the standard “3 + 3” rule. The total duration of treatment was 2 or 3 weeks. Results Between December 2013 and September 2014, 13 patients (2.5 mg/kg, n = 4; 5 mg/kg, n = 3; 7.5 mg/kg, n = 6) with refractory malignant ascites were enrolled. Bevacizumab was well tolerated, and the most common treatment-related adverse events were abdominal pain (5/13), abdominal distension (2/13), and fatigue (2/13). The dose-limiting toxicity at 7.5 mg/kg was grade 3 bowel obstruction (1/13). The maximum tolerated dose (MTD) was not reached. The overall response and disease control rates were 7.7 and 61.5%, respectively. Conclusions Intraperitoneal bevacizumab safe and well tolerated for treating malignant ascites, and the MTD was not reached at doses of 2.5 to 7.5 mg/kg. Intraperitoneal bevacizumab at 7.5 mg/kg weekly is recommended for further study to verify its anti-tumor activity. Trial registration: Clinical Trials NCT01852409.

show abstract

“…Third, preclinical and early clinical data demonstrate a role for BEV in the treatment of PC and/or ascites from CRC or ovarian cancer [ 28 – 31 ]. In a recent clinical study, Passot and colleagues determined intravenous (IV) and IP VEGF levels before and after CRS and HIPEC [ 32 ]. They found that the IP VEGF concentration increased significantly after surgery and that neoadjuvant BEV was associated with a lower IP VEGF level in a multivariate model.…”

Section: Introductionmentioning

confidence: 99%

BEV-IP: Perioperative chemotherapy with bevacizumab in patients undergoing cytoreduction and intraperitoneal chemoperfusion for colorectal carcinomatosis

et al. 2015

View full text Add to dashboard Cite

BackgroundSelected patients with peritoneal carcinomatosis (PC) from colorectal cancer (CRC) benefit from cytoreductive surgery (CRS) combined with intraperitoneal chemoperfusion (IPC). However, even after optimal cytoreduction, systemic and locoregional recurrence are common. Perioperative chemotherapy with bevacizumab (BEV) may improve the outcome of these patients.Methods/DesignThe BEV-IP study is a phase II, single-arm, open-label study aimed at patients with colorectal or appendiceal adenocarcinoma with synchronous or metachronous PC. This study evaluates whether perioperative chemotherapy including BEV in combination with CRS and oxaliplatin-based IPC results in acceptable morbidity and mortality (primary composite endpoint). Secondary endpoints are treatment completion rate, chemotherapy-related toxicity, pathological response, progression free survival, and overall survival.DiscussionThe BEV-IP trial is the first prospective assessment of the safety and efficacy of perioperative chemotherapy combined with anti-angiogenic treatment in patients undergoing CRS and IPC for colorectal peritoneal metastases.Trial registrationClinicalTrials.gov Identifier: NCT02399410 EudraCT number: 2015-001187-19 (registered March 9, 2015).

show abstract

Intraperitoneal vascular endothelial growth factor burden in peritoneal surface malignancies treated with curative intent: The first step before intraperitoneal anti-vascular endothelial growth factor treatment?

Cited by 11 publications

References 39 publications

Diagnostic and therapeutic strategies in peritoneal carcinomatosis from breast cancer – literature minireview

Diagnostic and therapeutic strategies in peritoneal carcinomatosis from breast cancer – literature minireview

Phase I study of intraperitoneal bevacizumab for treating refractory malignant ascites

BEV-IP: Perioperative chemotherapy with bevacizumab in patients undergoing cytoreduction and intraperitoneal chemoperfusion for colorectal carcinomatosis

Contact Info

Product

Resources

About